EQUAL ABPA Score 2024: A Tool to Measure Guideline Adherence for Managing Allergic Bronchopulmonary Aspergillosis.
Aspergillus
allergic bronchopulmonary mycosis
asthma
bronchiectasis
cystic fibrosis
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
05
10
2024
received:
28
08
2024
accepted:
10
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
27
10
2024
Statut:
ppublish
Résumé
Allergic bronchopulmonary aspergillosis (ABPA) is a complex lung disease associated with significant morbidity. The ABPA Working Group (AWG) of the International Society for Human and Animal Mycology (ISHAM) revised their management guidelines in 2024, but there is currently no standardised tool to assess adherence to these recommendations. We extracted key recommendations from the updated 2024 ISHAM-AWG guidelines, focusing on critical areas: screening and diagnosis of ABPA, managing acute and treatment-dependent ABPA, and monitoring treatment response. Each item was assigned a score ranging from zero to three. We assigned negative scores to interventions not recommended by the guidelines. We identified 38 items indicative of optimal clinical care for patients with ABPA. The score for screening asthmatics for ABPA was set at three points. For diagnosing ABPA, 16 items were included, with a score ranging from 12 to 16 points, depending on the specific components used (predisposing conditions, serum A. fumigatus-specific IgE and IgG, serum total IgE, blood eosinophil count and chest computed tomography). The management of acute ABPA comprised 11 items, with a maximum score of three points. For treatment-dependent ABPA, there were nine items (scores ranging from -3 to 6). Follow-up care comprised 10 items with a maximum score of 10-13 points, covering imaging, spirometry, testing serum total IgE levels and therapeutic drug monitoring. The EQUAL ABPA score has been developed as a comprehensive tool to quantify guideline adherence. Future studies will evaluate to which extent guideline adherence is associated with improved clinical outcomes for patients with ABPA.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13810Informations de copyright
© 2024 Wiley‐VCH GmbH. Published by John Wiley & Sons Ltd.
Références
R. Agarwal, V. Muthu, and I. S. Sehgal, “Relationship Between Aspergillus and Asthma,” Allergology International 72, no. 4 (2023): 507–520.
R. Agarwal, V. Muthu, I. S. Sehgal, et al., “Prevalence of Aspergillus Sensitization and Allergic Bronchopulmonary Aspergillosis in Bronchial Asthma: A Systematic Review of Indian Studies,” Lung India 40, no. 6 (2023): 527–536.
V. N. Maturu and R. Agarwal, “Prevalence of Aspergillus Sensitization and Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: Systematic Review and Meta‐Analysis,” Clinical and Experimental Allergy 45, no. 12 (2015): 1765–1778.
D. W. Denning, A. Pleuvry, and D. C. Cole, “Global Burden of Allergic Bronchopulmonary Aspergillosis With Asthma and Its Complication Chronic Pulmonary Aspergillosis in Adults,” Medical Mycology 51, no. 4 (2013): 361–370.
R. Agarwal, A. Chakrabarti, A. Shah, et al., “Allergic Bronchopulmonary Aspergillosis: Review of Literature and Proposal of New Diagnostic and Classification Criteria,” Clinical and Experimental Allergy 43, no. 8 (2013): 850–873.
R. Agarwal, I. S. Sehgal, V. Muthu, R. Dhar, and D. Armstrong‐James, “Allergic Bronchopulmonary Aspergillosis in India,” Clinical and Experimental Allergy 53, no. 7 (2023): 751–764.
R. Dhar, S. Singh, D. Talwar, et al., “Bronchiectasis in India: Results From the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry,” Lancet Global Health 7, no. 9 (2019): e1269–e1279.
J. D. Chalmers, E. Polverino, M. L. Crichton, et al., “Bronchiectasis in Europe: Data on Disease Characteristics From the European Bronchiectasis Registry (EMBARC),” Lancet Respiratory Medicine 11, no. 7 (2023): 637–649.
E. Polverino, P. C. Goeminne, M. J. McDonnell, et al., “European Respiratory Society Guidelines for the Management of Adult Bronchiectasis,” European Respiratory Journal 50, no. 3 (2017): 1700629.
A. T. Hill, A. L. Sullivan, J. D. Chalmers, et al., “British Thoracic Society Guideline for Bronchiectasis in Adults,” Thorax 74, no. Suppl 1 (2019): 1–69.
S. Budin, J. Salmanton‐Garcia, P. Koehler, J. Stemler, O. A. Cornely, and S. C. Mellinghoff, “Validation of the EQUAL Aspergillosis Score by Analysing Guideline‐Adherent Management of Invasive Pulmonary Aspergillosis,” Journal of Antimicrobial Chemotherapy 76, no. 4 (2021): 1070–1077.
S. C. Mellinghoff, P. Hartmann, F. B. Cornely, et al., “Analyzing Candidemia Guideline Adherence Identifies Opportunities for Antifungal Stewardship,” European Journal of Clinical Microbiology & Infectious Diseases 37, no. 8 (2018): 1563–1571.
R. Agarwal, I. S. Sehgal, V. Muthu, et al., “Revised ISHAM‐ABPA Working Group Clinical Practice Guidelines for Diagnosing, Classifying and Treating Allergic Bronchopulmonary Aspergillosis/Mycoses,” European Respiratory Journal 63, no. 4 (2024): 2400061.
O. A. Cornely, P. Koehler, D. Arenz, and S. C Mellinghoff, “EQUAL Aspergillosis Score 2018: An ECMM Score Derived From Current Guidelines to Measure QUALity of the Clinical Management of Invasive Pulmonary Aspergillosis,” Mycoses 61, no. 11 (2018): 833–836.
R. Sprute, E. Van Braeckel, H. Flick, et al., “EQUAL CPA Score 2022: A Tool to Measure Guideline Adherence for Chronic Pulmonary Aspergillosis,” Journal of Antimicrobial Chemotherapy 78, no. 1 (2022): 225–231.
R. Agarwal, A. N. Aggarwal, M. Garg, B. Saikia, and A. Chakrabarti, “Cut‐Off Values of Serum IgE (Total and A. Fumigatus ‐Specific) and Eosinophil Count in Differentiating Allergic Bronchopulmonary Aspergillosis From Asthma,” Mycoses 57, no. 11 (2014): 659–663.
R. Agarwal, D. Dua, H. Choudhary, et al., “Role of Aspergillus fumigatus‐Specific IgG in Diagnosis and Monitoring Treatment Response in Allergic Bronchopulmonary Aspergillosis,” Mycoses 60, no. 1 (2017): 33–39.
I. S. Sehgal and R. Agarwal, “Specific IgE Is Better Than Skin Testing for Detecting Aspergillus Sensitization and Allergic Bronchopulmonary Aspergillosis in Asthma,” Chest 147, no. 5 (2015): e194.
H. Tanimoto, Y. Fukutomi, H. Yasueda, et al., “Molecular‐Based Allergy Diagnosis of Allergic Bronchopulmonary Aspergillosis in Aspergillus fumigatus‐Sensitized Japanese Patients,” Clinical and Experimental Allergy 45, no. 12 (2015): 1790–1800.
V. Muthu, P. Singh, H. Choudhary, et al., “Diagnostic Cutoffs and Clinical Utility of Recombinant Aspergillus fumigatus Antigens in the Diagnosis of Allergic Bronchopulmonary Aspergillosis,” Journal of Allergy and Clinical Immunology: In Practice 8, no. 2 (2020): 579–587.
P. Lefebvre, M. S. Duh, M. H. Lafeuille, et al., “Burden of Systemic Glucocorticoid‐Related Complications in Severe Asthma,” Current Medical Research and Opinion 33, no. 1 (2017): 57–65.
H. Y. Huang, P. L. Lu, Y. L. Wang, T. C. Chen, K. Chang, and S. Y. Lin, “Usefulness of EQUAL Candida Score for Predicting Outcomes in Patients With Candidaemia: A Retrospective Cohort Study,” Clinical Microbiology and Infection 26, no. 11 (2020): 1501–1506.